作为动脉样硬化治疗目标的炎症酶:聚焦的外流
Yi-Jing Jin1,2, Zhuo-Yu An1,3, Zhi-Xuan Sun4
1Peking University Health Science Center, 100191 Beijing, China.
Reviews in cardiovascular medicine
|July 30, 2024
概括
向类似节点受体蛋白3 (NLRP3) 炎症酶,特别是其流动激活,为动脉样硬化提供了一种新的抗炎症策略. 这种方法解决了脂质代谢和心血管疾病中的炎症之间的关键联系.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管疾病 心血管疾病
- 分子生物学分子生物学
背景情况:
- 动脉样硬化是一种主要的心血管风险因素,由复杂的炎症和脂质代谢途径驱动.
- 内皮细胞损伤和炎症导致斑块形成,但精确的致病机制需要进一步阐明.
- 状受体蛋白3 (NLRP3) 炎症酶被认为是关键的调解者,将脂质代谢与炎症联系起来.
研究的目的:
- 审查NLRP3炎症酶在动脉样硬化免疫炎症途径中的作用.
- 整合目前关于NLRP3炎症酶激活的知识,强调流量.
- 突出针对出流通道的新型治疗策略,用于动脉样硬化治疗.
主要方法:
- 文献综述侧重于NLRP3炎症体及其在动脉样硬化病原发生中的作用.
- 对NLRP3炎症酶激活机制的当前研究分析,特别是流量.
- 在涉及的NLRP3途径中识别和讨论潜在的治疗点.
主要成果:
- 流被确定为NLRP3炎症酶的关键激活剂和调节剂.
- 现有的动脉样硬化治疗通常针对NLRP3下游的IL-1,而针对流量是一种较新的策略.
- 在动脉样硬化的情况下,参与外流的蛋白质对NLRP3炎症酶激活至关重要.
结论:
- NLRP3炎症体是动脉样硬化炎症通路的重要调节者.
- 向流是治疗动脉样硬化的有希望的治疗途径.
- 通过输出通道调节NLRP3炎症体,为动脉样硬化提供了一种强大的抗炎症策略.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
8.3K
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
7.5K
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
490
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
490
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
483
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
483
01:23Antihypertensive Drugs: Vasodilators
494
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
494
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K